stimulated [1%:2 months postantibiotic treatment. Disease-related concerns: Hepatic impairment: Patients with abnormal liver tests and/or liver disease should only be given rifapentine when absolutely necessary and under strict medical supervision. Monitoring of liver function tests (eg, serum transaminases) should be carried out prior to therapy and then every 2 to 4 weeks during therapy. Combination therapy should be discontinued if ALT is 5 times the upper limit of normal (ULN) even in the absence of liver dysfunction symptoms or 3 times ULN in the presence of symptoms (CDC, 2012). Porphyria: Use is not recommended in patients with porphyria; exacerbation is possible due to enzyme-inducing properties. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations: HIV-seropositive patients: Use of rifapentine during the initial phase of treatment in HIV seropositive patients has not been evaluated. Rifapentine should not be used during the continuation phase of treatment in HIV-seropositive patients; a higher rate of failure and/or relapse with rifampin-resistant organisms has been reported. Dosage form specific issues: Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). Other warnings/precautions: Appropriate use: Use with caution in patients with cavitary pulmonary lesions and/or positive sputum cultures after initial treatment phase and patients with bilateral pulmonary disease; higher relapse rates may occur in these patients. Compliance: Compliance with dosing regimen is absolutely necessary for successful drug therapy. Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur. Red/orange discoloration: Urine, feces, saliva, sweat, tears, skin, teeth, tongue, and CSF may be discolored to red/orange. Advise patients with dentures that permanent staining of dentures may occur. Monitoring Parameters Patients with preexisting hepatic problems should have liver function tests monitored (eg, serum transaminases) prior to therapy and then every 2 to 4 weeks during therapy. In treatment of latent infection with rifapentine and isoniazid combination therapy, patients with HIV infection, liver disorders, immediate postpartum ( 3 months after delivery), or regular ethanol use should have liver function (at least alanine aminotransferase [ALT]) monitored prior to therapy and then at subsequent clinical visits whose baseline testing is abnormal or for others at risk for liver disease (CDC, 2012). Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed in animal reproduction studies. Information related to the use of rifapentine in pregnant women is limited. Postnatal hemorrhages have been reported in the infant and mother with rifampin (another rifamycin) administration during the last few weeks of pregnancy. Monitoring of the prothrombin time in the mother and neonate is recommended following exposure late in pregnancy; treatment with vitamin K may be needed. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience diarrhea, lack of appetite, joint pain, nausea, vomiting, body tissue or body fluid discoloration, or denture discoloration. Have patient report immediately to prescriber signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), abnormal heartbeat, severe loss of strength and energy, chills, pharyngitis, bruising, bleeding, angina, tachycardia, dizziness, passing out, flu-like symptoms, muscle pain, swollen glands, cough, eye redness, shortness of breath, or signs of Clostridium difficile ( C. diff )-associated diarrhea (abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about rifapentine Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: rifamycin derivatives Consumer resources Rifapentine Rifapentine (Advanced Reading) Professional resources Rifapentine (AHFS Monograph) Other brands: Priftin Related treatment guides Tuberculosis, Active Tuberculosis, Latent] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Rifapentine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Rifamycin derivatives Related Drugs rifamycin derivatives rifampin , Rifadin , rifabutin , Priftin , Rimactane Tuberculosis, Latent rifampin , isoniazid , pyrazinamide , Rifadin , Nydrazid , Rimactane , Priftin , More... Tuberculosis, Active ciprofloxacin , Levaquin , levofloxacin , rifampin , moxifloxacin , Avelox , isoniazid , ethambutol , amikacin , gatifloxacin , More... feel sorry about
trustworthy Rifapentine every body
EmoticonEmoticon